AMLX Stock Recent News

Amylyx Pharmaceuticals, a biotech firm focusing on neurodegenerative disorders, has seen impressive Q1 2023 financial performance despite clinical uncertainties around its flagship product, Relyvrio. Relyvrio, an ALS treatment drug, generated $71.4 million in revenue, bolstering predictions of annual revenues surpassing $1 billion.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Margaret Olinger - Global Head of Commercial and CCO James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer and Co-Founder Conference Call Participants Corinne Jenkins - Goldman Sachs Marc Goodman - SVB Securities Ananda Ghosh - H.C. Wainwright Neena Bitritto-Garg - Citi Lindsey Allen Good afternoon and thank you for joining today to discuss our First Quarter 2023 Earnings.

The final trades of the day with the Fast Money traders.

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to loss of $0.93 per share a year ago.

Amylyx (AMLX) progresses with the phase II study of pipeline candidate AMX0035 for the treatment of Wolfram syndrome as it doses the first patient.

Amylyx Pharmaceuticals scored a major regulatory approval with its amyotrophic lateral sclerosis (ALS) drug last year. The drug's sales far surpassed expectations in its first quarter on the market inside the United States.

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock above its 50-day line Tuesday. The post Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment appeared first on Investor's Business Daily.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Margaret Olinger - Global Head of Commercial and CCO James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer and Co-Founder Conference Call Participants Geoff Meacham - Bank of America Umer Raffat - Evercore ISI Neena Bitritto-Garg - Citi Corinne Jenkins - Goldman Sachs Marc Goodman - SVB Securities Ananda Ghosh - H.C. Wainwright Operator Good afternoon.

AMLX got relyvrio approved through an interesting set of events. There are questions surrounding high price, low benefit, trial design, and so on.

Amylyx Pharmaceuticals, Inc. received a surprise approval for Relyvrio in ALS. The approval is great for the once-small company.